Galvus achieves significant improvements in Type 2 Diabetes study

New results on Galvus (vildagliptin), from Novartis, reveals that the drugf has a similar safety profile to placebo when added to anti-diabetic therapy in patients with Type 2 Diabetes and moderate or severe renal impairment. The study, presented at the 47th Annual Meeting of the European Association for the Study of Diabetes, also indicates that added to current therapy, Galvus resulted in significant improvements in glycemic control - elicited a statistically and clinically significant decrease in A1C (blood sugar) when added to anti-diabetic therapy, with A1C reductions of 0.7% (from baseline 7.9%) in moderate impairment and 0.9% (from baseline of 7.7%) in severe impairment. Additionally, the overall safety and tolerability of Galvus (50 mg) in patients with moderate or severe renal impairment were generally similar to placebo, though in patients with severe renal impairment, the incidence of infections and infestations was higher with vildagliptin than placebo.